VaccinesThyroid disease after HPV vaccination? The commission did not resolve the dispute!
What do Natural Therapy Specialists write?
The STOP NOP Association cites findings indicating a possible link between HPV vaccination and hypothyroidism and autoimmune thyroiditis.
The STOP NOP Association cites a study linking HPV4 vaccination with a serious autoimmune adverse event.
Plaintiffs in cases involving the Gardasil vaccine alleged, among other things, that it caused autoimmune disorders.
The STOP NOP Association says the commission did not determine whether the childhood vaccination schedule is associated with autoimmune diseases.
The STOP NOP Association links the deterioration in children's health, which coincided with the wider use of vaccination, to the occurrence of autoimmune diseases.
Hubert Czerniak claims that maintaining a child's TH2 state can lead to autoimmune diseases and therefore advocates starting vaccination at six months of age.
Prof. Sucharit Bhakdi describes autoimmune disease as the result of immune cells incorrectly recognizing the body's own antigens.
Prof. Sucharit Bhakdi cites a compilation of 87 cases of hepatitis after COVID-19 vaccination, 34 of which had no detected autoantibodies.
Prof. Sucharit Bhakdi indicates that in the hepatitis case described, a possible explanation was an immune attack on the spike protein, rather than autoimmunity.
Prof. Sucharit Bhakdi says that cases of encephalitis diagnosed as autoimmune have been described after mRNA vaccination, but that its cause often cannot be determined without examining tissue.
What does scientific research from PubMed · Europe PMC say?
We selected 6 studies with the best, positive results. This is a selection, not a full review of all research.
Total number of studies on this topic in PubMed: 3 182.
Aim of the study: To assess whether hepatitis B vaccination in adults is causally associated with autoimmune diseases. Such causation has been claimed based mainly on case reports and uncontrolled studies, and a syndrome, 'Autoimmune/autoinflammatory Disorder Induced by Adjuvants' (ASIA), has been claimed to be linked to immunization, particularly hepatitis B vaccination.
Results: Overall, no association between hepatitis B vaccination and the onset of autoimmune diseases was seen. The overall odds ratio was 1.06, with 95% confidence limits of 0.93-1.21, and there was no significant heterogeneity. Only one study showed a significant excess risk between hepatitis B immunization and autoimmune disease. Despite multiple case reports, there is no reliable scientific evidence that hepatitis B vaccinations cause autoimmune diseases.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: The role of vaccination in the development of Guillain-Barré syndrome (GBS) is controversial, although cases of GBS have been reported following a wide range of vaccines. A nested case-control study was conducted between January 2011 and December 2015 in three Chinese cities.
Results: Among the pediatric and adult populations, adjusted ORs for GBS occurrence within 180 days following vaccination were 0.94 (95% CI 0.54-1.62) and 1.09 (95% CI 0.88-1.32), respectively. No increased risk of GBS was detected for vaccination against hepatitis B, influenza, hepatitis A, varicella, rabies, live polio, diphtheria, acellular pertussis, tetanus, measles, mumps, rubella, Japanese encephalitis, or meningitis. Adjusted ORs for GBS recurrence after vaccination among pediatric and adult populations were 0.85 (95% CI 0.07-9.50) and 1.18 (95% CI 0.49-2.65), respectively. In this large retrospective study, we found no evidence of an increased risk of GBS or its recurrence among either pediatric (≤ 18 years) or adult (> 18 years) individuals within the 180 days following vaccinations of any kind, including influenza vaccination.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Individuals with autoimmune or immune-mediated diseases (AID) are more susceptible to infections and often experience worse outcomes if infected, underscoring the importance of vaccination. However, it remains unclear whether vaccine effectiveness (VE) differs between persons with and without AID.
Results: For the herpes zoster trial, 169,054 vaccinated individuals were matched to the same number of controls, including 10,994 AID individuals per group. Herpes zoster VE was 68.73 (95% CI 55.75-77.91) in the AID group and 60.30 (55.59-64.52) in the non-AID group (VE ratio: 1.14, 95% CI 0.93-1.30). Across four influenza seasons (2015/2016-2018/2019), between 1403,342 and 1713,064 individuals were included, including between 56,662 and 78,320 AID individuals. Influenza VE varied by outcome, season, and assumptions, but VE ratios remained near one in most analyses (VE ratios: -0.92-3.77), with all CIs including one. There was no evidence that VE differs meaningfully between individuals with and without AID, conditional on the included confounders. Both vaccines were similarly effective across groups, suggesting that VE is not reduced in patients with MS, IBD, or CIRD. Further research is needed to validate these findings for other AID and infections.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: The COVID-19 Vaccination in Autoimmune Diseases (COVAD) study aimed to assess short-term COVID-19 vaccination-related adverse events (AEs) in patients with RA.
Results: Of the 9462 complete respondents, 14.2% (n = 1347) had been diagnosed with RA; they had a mean (s.d.) age of 50.7 (13.7) years, 74.2% were women, and 49.3% were Caucasian. In total, 76.9% and 4.2% of patients with RA reported minor and major AEs, respectively. Patients with active and inactive RA had similar AE and hospitalization frequencies. Overall, AEs were reported more frequently by BNT162b2 and mRNA-1273 recipients and less frequently by BBV152 recipients compared with the rest. Major AE and hospitalization frequencies were similar across recipients of different vaccines. Patients receiving methotrexate and hydroxychloroquine reported fewer minor AEs than patients not taking them. Compared with healthy controls (HCs) and patients with other AIRDs, patients with RA reported similar total AEs, overall minor AEs, and hospitalizations.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Immunocompromised individuals face elevated risks of severe COVID-19, yet vaccination guidance for these populations continues to evolve.
Results: Most studies had short follow-up durations, likely reflecting higher-end estimates of vaccine effectiveness. Given moderate certainty of benefit and low certainty of harm, the panel strongly recommends the 2025-2026 COVID-19 vaccine for all immunocompromised individuals aged ≥6 months, with timing tailored to immunosuppressive therapy, clinical stability, and community transmission levels. Adjunct strategies—including vaccination of household contacts and early antiviral access—remain essential. Research priorities include defining immunologic correlates of protection, evaluating durability, optimizing vaccine timing, and improving real-world effectiveness and safety data.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Respiratory viruses—including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19), respiratory syncytial virus (RSV), and influenza—pose significant risks to immunocompromised patients, who experience weaker vaccine responses and higher morbidity.
Results: Research gaps remain in immunogenicity, durability, and clinical effectiveness, particularly for patients receiving B-cell-depleting therapies or in the early period after transplantation. Priority areas include defining correlates of protection, optimizing vaccine schedules, evaluating high-dose or adjuvanted formulations, and improving real-world effectiveness and safety data. Equity and access strategies are essential to ensure uptake among vulnerable populations. These guidelines aim to support evidence-based decision-making and highlight the need for harmonized, multi-virus research to inform tailored vaccination strategies for immunocompromised individuals.
“Not stated” does not mean nobody paid — the database does not always record it.
What do orthomolecular medicine doctors write?
Sources (15)
- Stowarzyszenie STOP NOP — Lekarze ostrzegają! Szczepionka HPV – Ogólnopolskie Stowarzyszenie Wiedzy o Szczepieniach "STOP NOP"
- Stowarzyszenie STOP NOP — Szczepienia – poznaj ich ryzyko i skuteczność – Ogólnopolskie Stowarzyszenie Wiedzy o Szczepieniach "STOP NOP"
- Stowarzyszenie STOP NOP — Dr n.med. Dorota Sienkiewicz „Bezpieczne szczepienia” – alternatywny kalendarz szczepień – Ogólnopolskie Stowarzyszenie Wiedzy o Szczepieniach "STOP NOP"
- Hubert Czerniak — Wyleczyć nieuleczalne – autyzm
- Prof. Sucharit Bhakdi — mRNA Vaccine Toxicity — M. Palmer i S. Bhakdi i in. (2023)
- Prof. Sucharit Bhakdi — mRNA vaccines against COVID-19 and their effects on the central nervous system
- Autoimmune diseases after hepatitis B immunization in adults: Literature review and meta-analysis, with reference to 'autoimmune/autoinflammatory syndrome induced by adjuvants' (ASIA). · Vaccine 2018
- Vaccines and the risk of Guillain-Barré syndrome. · Eur J Epidemiol 2020
- Influenza and herpes zoster vaccine effectiveness in autoimmune or immune-mediated diseases. · J Infect Public Health 2026
- COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis. · Rheumatology (Oxford) 2023
- IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19 Infections in Immunocompromised Patients. · Clin Infect Dis 2026
- IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19, Influenza, and RSV Infections in Immunocompromised Patients. · Clin Infect Dis 2026
- Orthomolecular Medicine News Service — VACCINATIONS: To Be or Not to Be
- Orthomolecular Medicine News Service — VACCINE ADJUVANTS AND EXCIPIENTS: Know what else comes through the needle?
- Orthomolecular Medicine News Service — Flu Vaccine: No Good Evidence
Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.